ReviewFrontiers in cellular and infection microbiology2024
Recent advances in gene-editing approaches for tackling antibiotic resistance threats: a review.
Review in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- CRISPR-based gene editing for antimicrobial resistance control in human medicine.Archives of microbiology · 2026Review
- Bacterial mutation dynamics emerging insights into virulence evolution and drug resistance. A review study.Frontiers in medicine · 2026Review
- Endophytic fungi as a source of antimicrobial compounds against emerging methicillin-resistantMycology · 2026Review
- Antimicrobial Resistance Profiles of Clinically Relevant Enterobacteriaceae Isolates: A Retrospective Study at a Southern Italian Hospital.Antibiotics (Basel, Switzerland) · 2025Article
- Evolutionary relationships and genetic diversity in theBiochemistry and biophysics reports · 2025Article
- Combining Advanced Therapies with Alternative Treatments: A New Approach to Managing Antimicrobial Resistance?Pharmaceutics · 2025Review
- Exploring the Probiotic Potential of Bacteroides spp. Within One Health Paradigm.Probiotics and antimicrobial proteins · 2025Review
- Engineering Useful Microbial Species for Pharmaceutical Applications.Microorganisms · 2025Review
- Microbial therapeutics for canine periodontal disease: current status and future perspectives.Frontiers in veterinary science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance, a known global health challenge, involves the flow of bacteria and their genes among animals, humans, and their surrounding environment. It occurs when bacteria evolve and become less responsive to the drugs designated to kill them, making infections harder to treat. Despite several obstacles preventing the spread of genes and bacteria, pathogens regularly acquire novel resistance factors from other species, which reduces their ability to prevent and treat such bacterial infections. This issue requires coordinated efforts in healthcare, research, and public awareness to address its impact on human health worldwide. This review outlines how recent advances in gene editing technology, especially CRISPR/Cas9, unveil a breakthrough in combating antibiotic resistance. Our focus will remain on the relationship between CRISPR/cas9 and its impact on antibiotic resistance and its related infections. Moreover, the prospects of this new advanced research and the challenges of adopting these technologies against infections will be outlined by exploring its different derivatives and discussing their advantages and limitations over others, thereby providing a corresponding reference for the control and prevention of the spread of antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.